Bernard Cambou
Keine laufenden Positionen mehr
Profil
Dr. Cambou is responsible for sourcing, researching, evaluating, negotiating, and monitoring investment opportunities in the life
sciences sector.
He has 22 years of international business and research and development experience in the pharmaceutical and biotechnology industries
He started his career with Roussel-Uclaf (now Aventis Pharma) as senior scientist in biotechnology research.
He later joined Farmitalia Carlo Erba (now Pharmacia) and then Rhone-Poulenc Rorer/RPR (now Aventis Pharma) in various research and development capacities.
While with Rhone-Poulenc Rorer, he spent two years in Japan with the joint venture RPR-Chugai Pharmaceuticals.
Bernard then moved into business development, relocating to the U.S.
as head of biotechnology evaluation for Centeon (now Aventis Behring), an RPR-Hoescht biopharmaceutical joint venture.
At Centeon he was involved in various in and out-licensing transactions most notably with Merck, Inhale Corp., Medarex and Kaketsuken (Japan).
He was also involved or led various M&A transactions such as Applied Immune Sciences (US), Delta Biotechnology (UK), and GenTrec (Germany).
Dr. Cambou is an engineer in Agronomy and majored in Microbiology at the National Institute of Agronomy in France.
He is a graduate in Molecular Biology from the Pasteur Institute.
He obtained his Ph.D.
from the University of Technology of Compiegne in Biochemistry and Enzymology and spent two years as a Post-Doctoral Fellow in Enzymology at Massachusetts Institute of Technology.
Dr. Cambou also received an M.B.A.
at Ecole Superieure des Sciences Economiques et Commerciales.
He relocated to Pittsburgh to join Birchmere Ventures as its first life sciences partner.
Ehemalige bekannte Positionen von Bernard Cambou
| Unternehmen | Position | Ende |
|---|---|---|
Cytomics Pharmaceuticals SA
 Cytomics Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Cytomics Pharmaceuticals is a biopharmaceutical company dedicated to discovering and developing drugs that control the degradation of proteins, to treat major human diseases. The company was founded in April 2000 in collaboration with Dominique Thomas (Research Director at the Center for Molecular Genetics of the CNRS) and Richard Benarous (Director of the Department for Infectious Diseases 'at the Cochin Institute of Molecular Genetics), both specialists recognized by the ubiquitin-proteasome protein degradation. | Vorsitzender | 09.11.2009 |
Cellatope Corp.
 Cellatope Corp. Pharmaceuticals: MajorHealth Technology Cellatope Corp. provides medical services. It develops research & diagnostic products and services for autoimmune diseases focusing on lupus. The company was founded by Alumna Valerie Pajak Glyptis in October, 2004 and is headquartered in Pittsburgh, PA. | Präsident | 01.12.2006 |
Birchmere Ventures, Inc.
 Birchmere Ventures, Inc. Investment ManagersFinance Birchmere Ventures Inc (Birchmere Ventures) is a venture capital firm founded in the year 1996 by Ned Renzi and Sean Sebastian. The firm is headquartered in Pittsburgh, Pennsylvania with an additional office in San Francisco. | Chief Investment Officer | 20.06.2005 |
Aventis Pharmaceuticals, Inc.
 Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | Corporate Officer/Principal | 01.05.2004 |
Pharmacia Corp.
 Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Pharmacia Corp. developed, manufactured and marketed pharmaceutical products. Prescription pharmaceuticals included general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. It also operated in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the group were pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. It was headquartered in Peapack, NJ. | Corporate Officer/Principal | 01.05.2004 |
Ausbildung von Bernard Cambou
| Université de Technologie de Compiègne | Doctorate Degree |
| ESSEC Business School | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
Human Genome Sciences, Inc.
 Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Health Technology |
Cellatope Corp.
Cellatope Corp. Pharmaceuticals: MajorHealth Technology Cellatope Corp. provides medical services. It develops research & diagnostic products and services for autoimmune diseases focusing on lupus. The company was founded by Alumna Valerie Pajak Glyptis in October, 2004 and is headquartered in Pittsburgh, PA. | Health Technology |
Aventis Pharmaceuticals, Inc.
Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | Health Technology |
Pharmacia Corp.
Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Pharmacia Corp. developed, manufactured and marketed pharmaceutical products. Prescription pharmaceuticals included general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. It also operated in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the group were pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. It was headquartered in Peapack, NJ. | Health Technology |
| Aventis Behring | Health Technology |
Birchmere Ventures, Inc.
Birchmere Ventures, Inc. Investment ManagersFinance Birchmere Ventures Inc (Birchmere Ventures) is a venture capital firm founded in the year 1996 by Ned Renzi and Sean Sebastian. The firm is headquartered in Pittsburgh, Pennsylvania with an additional office in San Francisco. | Finance |
Cytomics Pharmaceuticals SA
Cytomics Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Cytomics Pharmaceuticals is a biopharmaceutical company dedicated to discovering and developing drugs that control the degradation of proteins, to treat major human diseases. The company was founded in April 2000 in collaboration with Dominique Thomas (Research Director at the Center for Molecular Genetics of the CNRS) and Richard Benarous (Director of the Department for Infectious Diseases 'at the Cochin Institute of Molecular Genetics), both specialists recognized by the ubiquitin-proteasome protein degradation. | Health Technology |
